Prosecution Insights
Last updated: April 19, 2026
Application No. 17/865,875

ANTI-FIBROSIS AGENT AND METHOD OF PRODUCING EXTRACELLULAR VESICLE HAVING ANTI-FIBROSIS ACTION

Non-Final OA §102
Filed
Jul 15, 2022
Examiner
LANKFORD JR, LEON B
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujifilm Wako Pure Chemical Corporation
OA Round
3 (Non-Final)
70%
Grant Probability
Favorable
3-4
OA Rounds
3y 12m
To Grant
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allow Rate
496 granted / 714 resolved
+9.5% vs TC avg
Strong +31% interview lift
Without
With
+30.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 12m
Avg Prosecution
34 currently pending
Career history
748
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 714 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/14/25 is being considered by the examiner. Allowable Subject Matter Prosecution on the merits of this application is reopened on claims 5-15 considered unpatentable for the reasons indicated below: the IDS of 11/14/25. Applicant is advised that the Notice of Allowance mailed 10/3/25 is vacated. If the issue fee has already been paid, applicant may request a refund or request that the fee be credited to a deposit account. However, applicant may wait until the application is either found allowable or held abandoned. If allowed, upon receipt of a new Notice of Allowance, applicant may request that the previously submitted issue fee be applied. If abandoned, applicant may request refund or credit to a specified Deposit Account. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 5-7 & 12-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by LIU ZHI ET AL (CELL DEATH DISCOVERY, 2019). Zhi (Exosome Purification) teaches discloses a method for isolating EVs derived from stem cells by using PS-affinity (MagCapture) and reports that they promote neovascularization and alleviate inflammation after ischemia-reperfusion. Tim4 protein solidified magnetic beads were used to bind phosphatidyl serine (PS) on the surface of extracellular vesicles in the presence of metal ions, then neutral elution buffer containing EDTA was used to elute the exosome. By using the PS affinity method, isolation of exosomes with high purity and integrity was achieved. The exosome fraction protein content was assessed by the bicinchoninic acid (BCA) assay. As the claimed method and materials are the same as that of Zhi, the claims are anticipated by the reference and the antifibrotic property was necessary an inherent property of the EVs of Zhi. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLAINE LANKFORD whose telephone number is (571)272-0917. The examiner can normally be reached M-Th 8-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at 571-272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BLAINE LANKFORD Examiner Art Unit 1657 /BLAINE LANKFORD/Primary Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Jul 15, 2022
Application Filed
Nov 29, 2024
Non-Final Rejection — §102
Feb 24, 2025
Examiner Interview Summary
Feb 24, 2025
Applicant Interview (Telephonic)
Mar 04, 2025
Response Filed
Mar 04, 2025
Response after Non-Final Action
Jun 02, 2025
Final Rejection — §102
Aug 28, 2025
Response after Non-Final Action
Sep 02, 2025
Examiner Interview (Telephonic)
Sep 30, 2025
Examiner Interview (Telephonic)
Jan 15, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590133
IL-13/IL-4 SUPERKINES: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12590312
NR4A SUPER-REPRESSORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12589117
MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES
2y 5m to grant Granted Mar 31, 2026
Patent 12590954
NEURAL STEM CELL-INDUCED DIFFERENTIAL MEDIUM AND INDUCTION DIFFERENTIATION METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12590951
CULTURE MEDIUM AND CULTURE METHOD FOR PRIMARY CELLS OF INTESTINAL CANCER
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+30.6%)
3y 12m
Median Time to Grant
High
PTA Risk
Based on 714 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month